The 2018 Antimicrobial Resistance Benchmark compares how pharmaceutical companies are bringing AMR under control. It covers R&D, responsible manufacturing, appropriate access and stewardship.
"The AMR Benchmark brings much-needed clarity to how pharmaceutical companies approach AMR, which means investors can assess how pharmaceutical companies manage opportunities and risks created by drug-resistant infections. Such scrutiny by investors will spur pharma executives to greater activity."
Former Chair of the UK Review on AMR
"We desperately need new antibiotics, but we can’t let the new ones go to waste. The AMR Benchmark is an important tool to spur progress on innovation, appropriate use, and clean manufacturing, providing an independent assessment following the Davos Declaration and the Industry Roadmap released in 2016.
Professor of Law at Boston University and Executive Director of CARB-X
This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified”
Professor Dame Sally Davies, Chief Medical Officer and co-convener of the UN Inter-Agency Co-ordination Group on AMR
“To control drug resistance, pharma companies first need to stay in the game. The AMR Benchmark looks at the biggest players still making antibacterials and antifungals and addresses whether they are resilient enough for the tough market conditions.”
Executive Director Access to Medicine Foundation
View our detailed overview of each company’s performance
